Merck Receives FDA Approval to Market 'Cosopt'
Merck & CompanyMerck & Co., Inc., today announced that it received marketing clearance from the U.S. Food and Drug Administration for Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution). Cosopt is the first eye drop that combines a topical carbonic anhydrase inhibitor and a topical beta-blocking agent, commonly used, effective ophthalmic products with excellent safety profiles. Cosopt is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who do not respond adequately to beta-blockers alone.